TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1324534
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (3,000 anti-Xa units, one subcutaneous injection)
Study: 1324534
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5,000 U, subcutaneously three times a day)
Study: 1324534
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (low molecular weight heparin and low-dose heparin)
Study: 6383491
Drug: Bestatin 10
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin 10 mg orally three times daily for at least one year
Study: 6383491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further adjuvant treatment)
Study: 6383491
Drug: Bestatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin treatment
Study: 24135557
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab (0.5 mg) injections
Study: 19248192
Drug: Pantoprazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole treatment for 3 months
Study: 19248192
Drug: Pantoprazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole treatment for 6 months
Study: 12478843
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil (group A)
Study: 12478843
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection of prostaglandin E1 (PGE1) (group B)
Study: 12478843
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection of PGE1 (group B)
Study: 7700741
Drug: RSVIG 750
Normalized name: RSVIG
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVIG 750 mg/kg (high dose)
Study: 23061828
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (NAC) 1200 mg/daily
Study: 21813919
Drug: L-carnitine L-tartrate
Normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine L-tartrate (3 g, 2 g L-carnitine/d; n = 8)
Study: 19403652
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (tenofovir disoproxil fumarate and efavirenz)
Study: 19403652
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (tenofovir DF, lamivudine, and efavirenz)
Study: 19403652
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (tenofovir DF and efavirenz)
Study: 15022504
Drug: Topical medications
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medications (antifungals or disinfectants)
Study: 11286949
Drug: Colesevelam 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.8 g
Study: 11286949
Drug: Colesevelam 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.8 g with Simvastatin 10 mg
Study: 11286949
Drug: Colesevelam 2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 2.3 g
Study: 11286949
Drug: Colesevelam 2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 2.3 g with Simvastatin 20 mg
Study: 2446091
Drug: Aprotinin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high dosage, about 700 mg intravenously from the start of anaesthesia to the end of operation)
Study: 2446091
Drug: Aprotinin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high dosage)
Study: 22872770
Drug: Prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30 mg/d for 7 days
Study: 18560140
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy (CIMT) with modified opposition restriction orthosis (MORO), 5 hours/day, 7 days/week for 8 weeks
Study: 15831644
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DSE improvement or DWT > 0.8 cm
Study: 19433800
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg/day) and Vitamin E (400 IU/day)
Study: 8608485
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion 5-fluorouracil (5-FU) at doses ranging from 200-1100 mg/m2/day for 4 days
Study: 27834686
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) alone
Study: 1768563
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) + Indomethacin (75 mg) + Ketotifen (1 mg)
Study: 1768563
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) + Indomethacin (75 mg)
Study: 6816343
Drug: Tablets and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules taken with 100 ml of water
Study: 6816343
Drug: Tablets and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules taken with 25 ml of water
Study: 6816343
Drug: Tablets and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules taken while recumbent
Study: 6816343
Drug: Tablets and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules taken while standing
Study: 6816343
Drug: Small tablets
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small tablets
Study: 6816343
Drug: Liquid forms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid forms of medication (suspensions)
Study: 26797227
Drug: Emotional Freedom
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotional Freedom Techniques (EFT) group treatment program
Study: 15660024
Drug: Atorvastatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (all doses)
Study: 24888199
Drug: Atorvastatin (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (higher doses)
Study: 21186930
Drug: 1.8 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml/kg energy drink
Study: 21186930
Drug: 3.6 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 ml/kg energy drink
Study: 21186930
Drug: 5.4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.4 ml/kg energy drink
Study: 17592240
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (natural course)
Study: 12379552
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate and salmeterol combination (FSC)
Study: 10080557
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate injections every 2 weeks
Study: 10080557
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate injections every 6 weeks
Study: 27197855
Drug: Glucose alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose alone (25 g)
Study: 27197855
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (10 g) + glucose (15 g)
Study: 16652071
Drug: Gabapentin (peak
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (peak dose of 2,400 mg/d over 20 weeks)
Study: 16652071
Drug: Gabapentin (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,800 and 2,400 mg/day)
Study: 9336134
Drug: Accelerated Hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Hyperfractionated (AH) radiotherapy (1.6 Gy b.i.d. to a total dose of 54.4 Gy)
Study: 9336134
Drug: Accelerated Fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Fractionation (AF) of 30 Gy in 10 daily fractions
Study: 3887172
Drug: Amitriptyline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (mean dose: 57.8 mg per day, max 75 mg per day)
Study: 30024193
Drug: Therapists' affiliative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapists' affiliative tendencies and time elapsed in therapy
Study: 25395314
Drug: Chemotherapy (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (6 × 3-weekly cycles FE₁₀₀C)
Study: 25395314
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (letrozole 2.5 mg, daily for 18-23 weeks)
Study: 20146793
Drug: Supervised Nordic
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised Nordic walking twice a week for eight weeks
Study: 17459096
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate 200 mg/day (F group)
Study: 17459096
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily (O group)
Study: 17459096
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of orlistat and fenofibrate (OF group)
Study: 16189259
Drug: Telepaque (iopanoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepaque (iopanoic acid), 500 mg/d orally for 7 days
Study: 16189259
Drug: 131I therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I therapy after Telepaque
Study: 16189259
Drug: Carbimazole, 30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole, 30-40 mg daily until euthyroid followed by 131I
Study: 8885674
Drug: SPf66 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 malaria vaccine (1st dose)
Study: 8885674
Drug: SPf66 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 malaria vaccine (2nd dose)
Study: 8885674
Drug: SPf66 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 malaria vaccine (3rd dose)
Study: 8885674
Drug: Placebo (1st
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1st dose)
Study: 8885674
Drug: Placebo (2nd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2nd dose)
Study: 8885674
Drug: Placebo (3rd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3rd dose)
Study: 8885674
Drug: SPf66 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 malaria vaccine (local reactions)
Study: 8885674
Drug: SPf66 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 malaria vaccine (systemic side effects)
Study: 2065925
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10 mg.kg‐1.day‐1 for 1 month)
Study: 2065925
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (15 mg.kg‐1.day‐1 for 1 month)
Study: 6587751
Drug: Verapamil (Isoptin)
Normalized name: verapamil Extended Release Oral Tablet [Isoptin]
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (Isoptin) 120 mg X 3 for four weeks
Study: 22927454
Drug: intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent dosing schedule of aerosolized ribavirin
Study: 22927454
Drug: continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous dosing schedule of aerosolized ribavirin
Study: 16286540
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (30-microg, once weekly, intramuscular)
Study: 10371118
Drug: Chemotherapy (PVM:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (PVM: 80 mg/m2 Cisplatin on day 1, 2-3 mg/m2 Vindesine on day 1 and/or day 8, 8 mg/m2 Mitomycin C on day 1, followed by 400 mg/day UFT orally for 1 year)
Study: 10371118
Drug: Chemotherapy (PVM)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (PVM)
Study: 29783900
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg PO daily)
Study: 29783900
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg PO daily)
Study: 24503429
Drug: Warfarin prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescribed according to predicted warfarin dose based on VKORC1 and CYP2C9 genotypes
Study: 24503429
Drug: Warfarin prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescribed according to empirical clinician estimates
Study: 24503429
Drug: Average predicted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average predicted dose for stable dose patients
Study: 24503429
Drug: Average effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average effective dose for stable dose patients
Study: 24503429
Drug: Difference between
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difference between average predicted dose and actual dose
Study: 16191240
Drug: Donepezil (acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (acetylcholinesterase inhibitor), dosage and duration not specified
Study: 8853805
Drug: Immunoadsorption therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption therapy utilizing Prosorba column
Study: 8853805
Drug: Immunoadsorption therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption therapy
Study: 1346539
Drug: Pilopine Gel
Normalized name: pilocarpine hydrochloride Ophthalmic Gel [Pilopine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilopine Gel (pilocarpine hydrochloride)
Study: 28872380
Drug: Low-intensity training
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity training (HA-L)
Study: 18651608
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg nabumetone tablet formulation
Study: 17121035
Drug: Antibiotic plus
Normalized name: Triple Antibiotic Plus
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic plus vitamin E (Control)
Study: 31519364
Drug: Intrapleural fibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural fibrinolytic therapy (IFT)
Study: 30806130
Drug: Mixed pure
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed pure tones sound therapy
Study: 30806130
Drug: Broad band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad band noise (BBN) sound therapy
Study: 28831695
Drug: Simplest model
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplest model for insulin pharmacokinetics
Study: 28831695
Drug: Best model
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best model with two linear subcutaneous compartments
Study: 26425555
Drug: CC haplotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC haplotype (rs969885-rs987195)
Study: 19681940
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of two bar‐splinted SLActive implants with an implant‐retained mandibular overdenture
Study: 11443604
Drug: 18 grays
Normalized name: Baccharis sarothroides a.gray
DrugBank: Baccharis sarothroides whole (DB15502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 grays (Gy) of cranial radiation therapy
Study: 8576295
Drug: mebeverine plain
Normalized name: mebeverine
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mebeverine plain 135 mg, two capsules t.i.d.
Study: 8576295
Drug: mebeverine sustained
Normalized name: mebeverine
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mebeverine sustained release 200 mg (SR), two capsules b.i.d.
Study: 8576295
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (mebeverine plain and mebeverine SR)
Study: 2142109
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg a day)
Study: 2142109
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (MPA; 100 mg a day)
Study: 357069
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fenmetozole
Study: 357069
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 200 mg fenmetozole and 50 ml/70 kg ethanol
Study: 19752581
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of ARA-enriched triglyceride (SUNTGA40S; containing 240 mg ARA)
Study: 19752581
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil capsules (inactive placebo)
Study: 8891660
Drug: Control (pre-L-dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pre-L-dopa administration)
Study: 4027125
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (2.5 g) administered 1 h after mefenamic acid
Study: 4027125
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (2.5 g) and hyoscine butylbromide (20 mg) administered after mefenamic acid
Study: 4027125
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (20 mg) administered immediately after mefenamic acid
Study: 25159085
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (5,000 lx)
Study: 22729470
Drug: Structum (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structum (500 mg twice daily)
Study: 18451114
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 mg iv during induction of anesthesia
Study: 18451114
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 mg iv approximately 30 min before the end of surgery
Study: 18451114
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 mg iv (both groups)
Study: 16416368
Drug: Conventional diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diet supplying 35 nonprotein kcal and 1.1 g of protein/kg per day (group A, n = 11)
Study: 14569405
Drug: LCP supplemented
Normalized name: LCP-AtorFen
DrugBank: LCP-AtorFen (DB05769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCP supplemented formula (0.5 g/100 g fat linoleic acid metabolites, 0.8 g/100 g fat alpha‐linolenic acid metabolites)
Study: 6352884
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection 30 to 60 minutes before breakfast
Study: 6352884
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection 5 minutes prior to breakfast
Study: 27271658
Drug: High-concentration glucose
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration glucose solution (250 mL containing 50% glucose)
Study: 27271658
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation plus high-concentration glucose solution
Study: 27271658
Drug: 8.5% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.5% amino acids solution
Study: 27271658
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral supplementation only)
Study: 16163098
Drug: Infiltration solutions
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration solutions at body temperature (37 degrees C)
Study: 16163098
Drug: Infiltration solutions
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration solutions at room temperature (24 degrees C)
Study: 10472853
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg with norethindrone acetate 0.1 mg
Study: 10472853
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg with norethindrone acetate 0.25 mg
Study: 10472853
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg with norethindrone acetate 0.5 mg
Study: 10472853
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg (unopposed)
Study: 9087885
Drug: Treatment suggested
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment suggested by the trained ART (N = 21)
Study: 9087885
Drug: Treatment suggested
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment suggested by ART
Study: 1846790
Drug: Dichloroacetate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (50 mg/kg body weight)